8-K: Coeptis Therapeutics Holdings Appoints New Auditor, Astra Audit & Advisory, Replacing Turner, Stone & Company

Coeptis Therapeutics Holdings has changed its independent registered public accounting firm from Turner, Stone & Company to Astra Audit & Advisory, effective immediately on September 24, 2024.

Summary

• Coeptis Therapeutics Holdings, Inc. has appointed Astra Audit & Advisory, LLC as their new independent registered public accounting firm, effective September 24, 2024.
• This change was approved by the Audit Committee and the Board of Directors.
• Turner, Stone & Company, LLP, the previous auditor, was dismissed on the same date.
• Turner's audit reports for the fiscal years ending December 31, 2023 and 2022 did not contain any adverse opinions, disclaimers, or qualifications, except for a going concern explanatory paragraph.
• There were no disagreements or reportable events between Coeptis and Turner during the fiscal years 2022 and 2023, and the subsequent interim periods through September 24, 2024.
• Coeptis has confirmed that they did not consult with Astra regarding accounting principles, audit opinions, or internal controls prior to their appointment.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing a routine change of auditor. The going concern paragraph in the previous audit report is a slight negative, but the lack of disagreements is a positive.

Positives

• The transition to a new auditor was approved by both the Audit Committee and the Board of Directors.
• Turner, Stone & Company's audit reports did not contain any adverse opinions or disclaimers, indicating no major issues with the previous audits.
• There were no disagreements or reportable events between the company and the previous auditor, suggesting a smooth relationship.

Negatives

• The dismissal of the previous auditor, Turner, Stone & Company, may raise questions about the reasons for the change, although no specific issues were cited.
• The inclusion of a going concern explanatory paragraph in Turner's audit reports could indicate potential financial challenges for the company.

Risks

• The change in auditors could lead to increased scrutiny from investors and regulators.
• The going concern explanatory paragraph in the previous auditor's reports suggests potential financial instability that needs to be monitored.
• Any future disagreements with the new auditor could lead to further complications and uncertainty.

Industry Context

Changes in auditors are not uncommon, but they can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting. It is important to monitor the company's financial statements and any future filings for any changes or issues.

Comparison to Industry Standards

• Auditor changes are a normal part of corporate governance, but the reasons for the change are often scrutinized by investors.
• Companies like Coeptis, which are in the biotech sector, often face financial challenges, so the going concern paragraph is not unusual but should be monitored.
• The lack of disagreements with the previous auditor is a positive sign, as it suggests no major accounting or auditing issues.

Stakeholder Impact

• Shareholders may be concerned about the change in auditors and the going concern paragraph, but the lack of disagreements with the previous auditor is reassuring.
• Employees may be indirectly affected by any changes in financial reporting or scrutiny.
• Creditors and suppliers may also monitor the company's financial health and any changes in its financial reporting.

Key Dates

Keywords

auditor, accounting firm, Astra Audit & Advisory, Turner, Stone & Company, financial statements, audit, Coeptis Therapeutics, SEC, 8-K